You might also like
Inogen, Inc. (Nasdaq: INGN) is a medical technology company specializing in respiratory health. It develops, manufactures, and markets innovative products designed to improve the quality of life for patients with chronic respiratory conditions. The company's offerings include portable oxygen concentrators and airway clearance devices, which are sold globally through direct sales, distributors, and partnerships with healthcare providers.
- Portable Oxygen Concentrators (POCs) - Provides battery-powered devices like the Inogen One® and Inogen Rove® systems that deliver supplemental oxygen 24/7, enhancing patient mobility and reducing reliance on stationary oxygen concentrators and oxygen tanks.
- Inogen One® - Offers continuous oxygen delivery for patients at home or on the go.
- Inogen Rove® - Features advanced portability and usability for active patients.
- Simeox® Product - Delivers airway clearance and mucus management for patients with bronchiectasis, cystic fibrosis, or chronic obstructive pulmonary disease (COPD). Used in pulmonary rehabilitation centers and at home, with availability in Europe, Asia, and the Middle East.
- Rental Revenue - Provides oxygen concentrators to patients on a rental basis, ensuring accessibility and affordability for long-term respiratory care.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Kevin R.M. Smith ExecutiveBoard | Chief Executive Officer | Kevin R.M. Smith is the Chief Executive Officer of Inogen, Inc. since November 2023, where he also serves as President and a member of the Board of Directors. Previously, he held leadership roles at Sirtex Medical Limited and OncoSec Medical. | View Report → | |
Gregoire Ramade Executive | Executive Vice President, Chief Commercial Officer | Gregoire Ramade currently serves as the Executive Vice President, Chief Commercial Officer at INGN since January 2, 2024. He previously served as Senior Vice President of International Sales from November 6, 2023 to January 2, 2024. | ||
Michael Bourque Executive | Executive Vice President, Chief Financial Officer, and Corporate Treasurer | Michael Bourque is currently serving as the Executive Vice President, Chief Financial Officer, and Corporate Treasurer at Inogen with his role effective on March 4, 2024. Previously, he held CFO roles at Chase Corporation, Keystone Dental Inc., Analogic Corporation, and Axcelis Technologies. | ||
Heather Rider Board | Member of the Board of Directors (Chairperson, Nominating and Governance Committee) | Board of Directors at ProSomnus | Heather Rider has served on the Board of Directors at INGN since 2014 and currently chairs the Nominating and Governance Committee while serving on the Compensation Committee since October 2020. | |
Kevin King Board | Chairperson of the Compliance Committee | Board of Directors of Turing Medical | Kevin King has served on the Board of Directors at Inogen, Inc. since 2022 as the Chairperson of the Compliance Committee and a member of the Audit Committee. He previously served as the Chairperson of the Compensation Committee from March 2022 to March 2024 and brings decades of leadership experience in the healthcare and IT sectors. | |
Mary Kay Ladone Board | Director on the Board of Inogen | Member of the Audit Committee and Compensation Committee at Bioventus, Inc. ; Chair of the Audit Committee and Member of the Nominating and Governance Committee at Kestra Medical Technologies ; Board Member at Novanta Inc. | Mary Katherine (Mary Kay) Ladone is an accomplished executive with over 30 years of experience in leadership roles in global healthcare companies, currently serving on Inogen's Board since March 22, 2022. |
-
Given the continued decline in rental revenue due to lower average billing rates and a shift towards private payers, what specific strategies are you implementing to address this trend and mitigate the impact of the shift from traditional Medicare to Medicare Advantage plans?
-
With the significant reduction in your direct-to-consumer sales force leading to a 21.3% decrease in DTC sales in Q4 2024, how do you plan to return this channel to growth in the next 1 to 2 years while maintaining profitability, and are there further rightsizing measures expected in 2025?
-
You have projected a 5%-6% revenue growth for full-year 2025, but your first quarter guidance indicates only 1%-4% growth. Given this slow start and your expectation of lower growth in the B2B channel compared to the 30% growth in 2024, what factors are driving your confidence in achieving the full-year growth target, and how will you address potential seasonality and channel challenges?
-
With the upcoming introduction of Simeox and the Yuwell collaboration, you expect gross margins to decline to 43%-45% in 2025 from 46.1% in 2024. Can you elaborate on how these initiatives are impacting margins, and what steps are being taken to offset the anticipated 100 basis points negative impact on gross margins?
-
Considering the complexities in obtaining reimbursement for Simeox, including the need for clinical data and engagement with key opinion leaders and CMS, what are the potential risks and timelines associated with securing reimbursement, and how might delays affect your strategy and financial outlook for Simeox's commercial launch in the U.S.?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Caire Medical | A significant manufacturing competitor in the long-term oxygen therapy market, noted as a subsidiary of NGK Spark Plug. |
DeVilbiss Healthcare | A significant manufacturing competitor in the long-term oxygen therapy market, noted as a subsidiary of Drive Medical. |
O2 Concepts | A significant manufacturing competitor in the long-term oxygen therapy market. |
Precision Medical | A significant manufacturing competitor in the long-term oxygen therapy market. |
Gas Control Equipment | A significant manufacturing competitor in the long-term oxygen therapy market, noted as a subsidiary of Colfax. |
Nidek Medical | A significant manufacturing competitor in the long-term oxygen therapy market. |
3B Medical | A significant manufacturing competitor in the long-term oxygen therapy market. |
SysMed | A significant manufacturing competitor in the long-term oxygen therapy market. |
A significant manufacturing competitor in the long-term oxygen therapy market. | |
Belluscura | A significant manufacturing competitor in the long-term oxygen therapy market. |
Respironics | A subsidiary of Koninklijke Philips N.V., which announced in early 2024 that it was leaving the U.S. portable oxygen concentrator market until further regulatory assessments but continues to have product in the market. |
Lincare, Inc. | A market leader in providing respiratory therapy products, noted as a subsidiary of the Linde Group. |
Apria Healthcare, Inc. | A market leader in providing respiratory therapy products. |
A market leader in providing respiratory therapy products. | |
Rotech Healthcare, Inc. | A market leader in providing respiratory therapy products. |
A market leader in providing respiratory therapy products. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Medicare’s service reimbursement programs | Reimbursement for rental services | Rental | 2024: 9.5% of total revenue , 56.3% of rental revenue , A/R $1.1M (3.7% of total) as of 12/31/24 ; 2023: 13.7% of total revenue , 67.7% of rental revenue , A/R $2.1M (4.9% of total) as of 12/31/23 ; 2022: 11.6% of total revenue , 77.0% of rental revenue. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Physio-Assist SAS and PhysioAssist GmbH | 2023 | Inogen, Inc. acquired these companies for a cash consideration of $32,250,000 at closing with an additional earnout potential of up to $13,000,000 (or $11,000,000 under certain conditions) tied to U.S. FDA milestones, adding the CE-marked Simeox airway clearance device that expands Inogen’s presence in global respiratory care markets. |
New Aera, Inc. | 2019 | Inogen, Inc. completed the merger with New Aera, Inc. for up to $101.9 million (including $70.4 million upfront and up to $31.4 million in earnouts) to strengthen its position in the oxygen therapy and non-invasive ventilation market by acquiring the FDA-cleared Tidal Assist Ventilator (TAV) system, with the deal including assumptions of various assets and liabilities and escrow adjustments for indemnification. |
Recent press releases and 8-K filings for INGN.
- Q4 Financial Highlights: Revenue grew by 5.5% to $80.1 million, driven by strong domestic (up 24.1%) and international (up 31.5%) B2B performance, with improved gross margin (45.3% vs. 37.1%) and a reduction in operating loss from $29.0M to $11.4M
- Full-Year & Guidance Update: Full-year revenue increased by 6.4% to $335.7 million, with 2025 guidance expecting revenue of $352–$355 million
- Strategic Collaboration: Finalized a partnership with Yuwell Medical, involving a $27.2 million investment for a 9.9% stake, aimed at expanding market reach—particularly for stationary products in China and the U.S.
- Profitability & Financial Position: Reported a GAAP net loss of $9.8 million alongside improved adjusted measures, a robust cash position of $117.4 million, and no outstanding debt
- Product Innovation: Launched the latest portable oxygen concentrator, Rove 4, and secured FDA clearance for the Simeox airway clearance device, bolstering its innovation pipeline
- Inogen Inc. has entered a strategic collaboration with Yuwell to expand its respiratory product portfolio and global reach.
- The partnership is designed to enhance Inogen’s innovation pipeline and accelerate its entry into the Chinese market while boosting product distribution in the United States and select territories.
- Yuwell will invest $27.2 million for a 9.9% equity stake, strengthening Inogen’s balance sheet, with the equity purchase expected to close in Q1 2025.
- Preliminary Q4 2024 revenue is estimated between $79.0M and $80.0M, reflecting 4%-5% year-over-year growth.
- The full year 2024 revenue is estimated between $334.5M and $335.5M, exceeding prior guidance and showing 6% year-over-year growth.
- The announcement is part of the Form 8-K filing and details remain preliminary pending audited financial statements.